Gilead Director Anthony Welters Exercises Options and Sells Shares

What Happened
Anthony Welters, a director of Gilead Sciences (GILD), exercised stock options and sold shares on August 26, 2026. He exercised options to acquire 7,718 shares at $60.67 (cost $468,251) and 10,282 shares at $61.35 (cost $630,801) — total exercise cost ~$1,099,052. On the same day he disposed of 18,000 shares in multiple open-market sales (3,118; 4,600; 3,402; 6,880) for aggregate gross proceeds of approximately $2,675,218. The filing also shows derivative dispositions at $0 for the exercised option lots, consistent with settlement/surrender related to the exercises.

Key Details

• Transaction date: August 26, 2026; Form 4 filed August 27, 2026 (timely filing).
• Option exercises: 7,718 shares @ $60.67 ($468,251) and 10,282 shares @ $61.35 ($630,801). (Transaction code M = exercise/conversion of derivative.)
• Open-market sales: total 18,000 shares sold for ~$2,675,218 (transaction code S = sale). Reported sale prices spanned roughly $147.57–$149.58 (see footnotes for exact ranges).
• Footnotes: Transactions were executed pursuant to a Rule 10b5-1 trading plan adopted May 27, 2026. Vesting notes in the filing indicate these options were fully vested (vested/vesting info from 2020–2021 grants).
• Shares owned after transaction: not disclosed in this Form 4 filing.
• Transaction codes: M = option exercise, S = open-market sale. No late filing indication in this record.

Context

• The pattern (option exercise followed by same‑day sales and $0 derivative dispositions) is common when insiders exercise options and either immediately sell some or all shares to cover exercise costs, taxes, or to rebalance holdings. This filing reports the mechanics and amounts but does not state Welters’ motives.
• The 10b5-1 plan note means the sales were executed under a pre-established trading plan, which can help insulate trades from claims of opportunistic timing.